

# Search Results -

Term	Documents
(3 AND 4).DWPI.	3

US Patents Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Disawent World Patents lindex

BM Technical Disclosure Bulletins

	13	and	14		]	
Refine Search:				₹		Clear

# Search History

Today's Date: 6/8/2000

<b>DB Name</b>	<u>Query</u>	Hit Count	Set Name
DWPI	13 and 14	3	<u>L5</u>
DWPI	lung or pulmonary or inhal\$6	21948	<u>L4</u>
DWPI	11 or 12	62	<u>L3</u>
DWPI	glucagon adj like adj peptide adj (1 or i)	45	<u>L2</u>
DWPI	(glp adj (1 or i))	52	<u>L1</u>



### Generate Collection

### Search Results - Record(s) 1 through 3 of 3 returned.

1. Document ID: AU 9926596 A, WO 9940788 A1

L7: Entry 1 of 3

File: DWPI

Aug 30, 1999

DERWENT-ACC-NO: 1999-527332

DERWENT-WEEK: 200003

COPYRIGHT 2000 DERWENT INFORMATION LTD

TITLE: Increasing urine flow by administering peptides or peptide agonists

L7: Entry 1 of 3

File: DWPI Aug 30, 1999

DERWENT-ACC-NO: 1999-527332

DERWENT-WEEK: 200003

COPYRIGHT 2000 DERWENT INFORMATION LTD

TITLE: Increasing urine flow by administering peptides or peptide agonists

#### ABTX:

NOVELTY - Increasing urine flow (I) in an individual comprising administering an exendin or exendin agonist, or a  $\underline{GLP-1}$  (glucagon-like peptide) or  $\underline{GLP-1}$  agonist.

#### ABTX:

(1) decreasing the concentration of potassium (II) in an individual's urine, comprising administering an exendin or exendin agonist, or GLP-1 or a GLP-1 agonist;

#### ABTX:

(2) preventing or alleviating a condition/disorder associated with toxic hypervolemia (III), comprising administering an exendin or exendin agonist, or GLP-1 or a GLP-1 agonist;

#### ABTX:

(3) inducing rapid diuresis (IV) comprising administering an exendin or exendin agonist, or GLP-1 or a GLP-1 agonist;

#### ABTX:

(4) preparing an individual for a surgical procedure (V) comprising administering an exendin or exendin agonist, or <u>GLP-1</u> or <u>a GLP-1</u> agonist;

#### ABTX:

(5) increasing renal plasma flow and glomerular filtration rate (VI) comprising administering an exendin or exendin agonist, or <a href="GLP-1">GLP-1</a> or a GLP-1 agonist;

#### ABTX:

(6) treating pre-eclampsia or eclampsia of pregnancy (VII) comprising administering an exendin or exendin agonist, or GLP-1 or a GLP-1 agonist;

## ABTX:

(7) increasing cardiac contractility (VIII) comprising administering an exendin or exendin agonist, or GLP-1 or a GLP-1 agonist;

#### ABTX:

(8) treating a condition or disorder that can be alleviated by increasing cardiac contractility (XI) comprising administering an exendin or exendin agonist, or GLP-1 or a GLP-1 agonist; and

#### ABTX:

(9) pharmaceutical compositions containing an exendin or exendin agonist, or a

(9) pharmaceutical compositions containing an exendin or exendin agonist, or a GLP-1 or a GLP-1 agonist, for use in all the above methods.

#### ABTX:

MECHANISM OF ACTION - GLP-1 stimulates insulin secretion from pancreatic cells.

#### ABTX:

USE - The new methods using an exendin, exendin agonist, <u>GLP-1</u> or <u>GLP-1</u> agonist are useful for increasing urine flow, decreasing potassium concentration in urine, preventing or alleviating a disorder associated with toxic hypervolemia, inducing rapid diuresis, preparing an individual for surgical procedure, increasing renal plasma flow and glomerular filtration rate, treating pre-eclampsia or eclampsia of pregnancy, and increasing a condition/disorder that can be alleviated by increasing cardiac contractility (claimed). Method (III) is useful for treating or alleviating renal failure, congestive heart failure, nephrotic syndrome, <u>pulmonary</u> edema and cirrhosis, or preferably hypertension. Method (IX) is useful for treating congestive heart failure, <u>pulmonary</u> edema, systemic edema or renal failure (claimed).

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWC | Draw Desc | Image |

File: DWPI

2. Document ID: EP 941114 A1, WO 9820895 A1, ZA 9710182 A, AU 9748637 A

.

DERWENT-ACC-NO: 1998-297611

DERWENT-WEEK: 199942

L7: Entry 2 of 3

COPYRIGHT 2000 DERWENT INFORMATION LTD

TITLE: Treatment of diseases associated with impaired appetite regulation e.g. obesity - by administration of the proglucagon fragment <u>GLP-1</u>(1-45), or its fragment, analogue or amide

L7: Entry 2 of 3

File: DWPI

Sep 15, 1999

Sep 15, 1999

DERWENT-ACC-NO: 1998-297611

DERWENT-WEEK: 199942

COPYRIGHT 2000 DERWENT INFORMATION LTD

TITLE: Treatment of diseases associated with impaired appetite regulation e.g. obesity - by administration of the proglucagon fragment  $\underline{GLP-1}$  (1-45), or its fragment, analogue or amide

#### ABTX

Treatment or prevention of diseases or disorders associated with impaired appetite regulation or feeling of satiety comprises administration of (i) GLP-1(1-45) (where GLP-1 is glucagon-like peptide-1), (ii) a fragment or analogue of GLP-1(1-45), or (iii) a C-terminal amide of a compound as described in (i) or (ii).

### ABTX:

USE - The process may be used e.g. in treatment of obesity. Administration is especially parenteral, nasal, <u>pulmonary</u>, transdermal, rectal, buccal or vaginal. Dosage of active agent is 10 mu g/kg/day to 5 mg/kg/day.

Full Title Citation Front Review Classification Date Reference Claims KWC Draw Desc Image

3. Document ID: WO 9001540 A, AU 8942166 A, CA 1320162 C, EP 428615 A, EP 428615

A4, JP 04501204 W

L7: Entry 3 of 3

File: DWPI

Feb 22, 1990

DERWENT-ACC-NO: 1990-083499

DERWENT-WEEK: 199011

COPYRIGHT 2000 DERWENT INFORMATION LTD

TITLE: Heterologous protein expression in prokaryotic host - using 3' truncated chloramphenicol acetyl-transferase gene to stably express hybrid protein

L7: Entry 3 of 3

File: DWPI

Feb 22, 1990

DERWENT-ACC-NO: 1990-083499

DERWENT-WEEK: 199011

COPYRIGHT 2000 DERWENT INFORMATION LTD

TITLE: Heterologous protein expression in prokaryotic host - using 3' truncated chloramphenical acetyl-transferase gene to stably express hybrid protein

#### ABTX:

(A) A bacterial expression vector capable of enhancing the level of expression of non-stable, bacterially produced heterologous polypeptide s is claimed comprising a hybrid gene having in sequential order, a 3' truncated chloroamphenicol acetyltransferase (CAT) gene sequence (I) linked to a heterologous gene sequence (II) encoding a mammalian polypeptide (III) selected from amyloid protein A4-751 insert sequence, glucagon-like peptide I, adipsin/D, lung surfactant protein SP-B and lung surfactant proetin SP-C, where the polypeptide is normally not recoverable in bacterial expression systems, whereby the truncated CAT gene sequence is capable of rendering the resulting fusion protein resistant to proteolytic degradation.

	Generate C	3	
	<b>Construction</b>	one de la companya d	
<b></b>	Term	Documents	
11	1 (1 111	Documents	

Display Format: Change Format

3 of 3